Rank #1971GLUE

Monte Rosa Therapeutics, Inc.

$19.16

4.81% (Daily)

Market Cap

$1.46B

Revenue

$181.54M

Rank by MCap

#1971

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Markus Warmuth M.D.

Headquarters

Boston, MA

Employees

147

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment o...